Chronic Obstructive Pulmonary Disease

1269 Words6 Pages
Glycopyrronium- Chronic Obstructive Pulmonary Disease Introduction The critical appraisal of a research article is a method of examining its validity, value and relevance to study. This assignment will focus on critically appraising a research article which evaluated the safety and efficacy of a drug (Glycopyrronium) used for chronic obstructive pulmonary disease, against a second drug (Tiotropium) used in the treatment of the same condition. Chronic obstructive pulmonary disease (COPD) is the name used for diseases related to the lungs, which cause breathing difficulties due to the narrowing of airways in the lung. Patients suffering from COPD experience symptoms of breathlessness when enduring physical activity, a persistent cough with…show more content…
I used keywords ‘glycopyrronium’ and ‘COPD’. Going through the results, I came across an article titled; “A blinded evaluation of the efficacy and safety of glycopyrronium, a once-daily long-acting muscarinic antagonist, versus tiotropium, in patients with COPD: the GLOW5 study” I chose to critically appraise this article as it evaluated the efficacy and safety of Glycopyrronium against Tiotropium, another mainly used drug in the treatment of COPD. A randomized controlled trial approach was used in this study. Over a period of 12 weeks, the blinded double dummy method was used where neither the participants nor the people giving the intervention know what it is. Due to both drugs having specific inhalation devices, each had a placebo, hence masking the identity of the drug. The advantages of the randomized controlled trial approach are that it allows for a thorough evaluation of the variables, there is potential for the eradication of bias results and this type of trial can be used to give a meta-analysis. However, this type of trial can be expensive, time consuming and can be ethically challenging or stopped if extensive adverse effects are seen. The baseline characteristics used in this trial for the participants were men and women aged ≥40 with moderate to severe COPD (stage II or stage III), who were current or ex-smokers that had or have been smoking for 10 years or more. 980 participants were
Open Document